Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia
NCT05316493Phase 3Recruiting
- Start
- Jun 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of megestrol and avatrombopag in endometrial atypical hyperplasia (AEH) (4 arms). Primary endpoint: Pathological complete response rates at 28 weeks. Started Jun 2022; status: recruiting.
02
Drugs
megestrolavatrombopag
03
Conditions
endometrial atypical hyperplasia (AEH)
Beyond the preview
Go deeper on NCT05316493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316493.